Article
OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer
16 Jan 2019
Abstract excerpt
No abstract is available from the source.
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.